Sun BioPharma ^{Filed, US Offering, Removed, Nasdaq: SNBP}

We are a clinical-stage biopharmaceutical company focused on developing SBP-101, a proprietary small molecule polyamine metabolic inhibitor delivered subcutaneously for the treatment of patients with pancreatic cancer and other solid tumor cancers. We have an exclusive license to the worldwide rights to this compound from the University of Florida Research Foundation (“UFRF”), and we obtained US Orphan Drug Status for SBP-101 in 2014. In the second quarter of 2020, the Food and Drug Administration (“FDA”) granted Fast Track designation to SBP-101. To date, we have invested approximately $25 million in developing SBP-101, which we are initially targeting as a first-line therapy for metastatic pancreatic ductal adenocarcinoma (“PDA”) in combination with gemcitabine and nab-paclitaxel (“Gem + Nab”), a chemotherapy standard of care. We recently reported positive interim Phase 1a data demonstrating SBP-101 (as first-line therapy in combination with Gem + Nab) was generally well tolerated by PDA patients and presented a 62% objective response rate, which is more than double contemporary response rates for Gem + Nab alone. In addition, 69% of patients experienced a reduction of greater than 75% in CA 19-9 serum levels, a biomarker negatively associated with long-term survival benefit in PDA. We believe SBP-101 represents a novel approach that is differentiated from current programs targeting pancreatic and other solid tumor cancers and, if approved, has the potential to significantly impact clinical outcomes of patients with cancer.